Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.
作者信息
Rios Rafael S, Zheng Kenneth I, Targher Giovanni, Byrne Christopher D, Zheng Ming-Hua
机构信息
Department of Hepatology, MAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona 37126, Italy.
出版信息
Chin Med J (Engl). 2020 Nov 20;133(22):2743-2745. doi: 10.1097/CM9.0000000000000989.
Abstract
摘要
相似文献
1
Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.非酒精性脂肪性肝病的无创纤维化评估
Chin Med J (Engl). 2020 Nov 20;133(22):2743-2745. doi: 10.1097/CM9.0000000000000989.
2
Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.致编辑的信：使用机器学习模型诊断非酒精性脂肪性肝病中的纤维化和肝硬化
Hepatology. 2023 May 1;77(5):E103-E104. doi: 10.1097/HEP.0000000000000209. Epub 2023 Jan 3.
3
Settling the Score: Which Fibrosis Screening Tool Is the Most Reliable for Nonalcoholic Fatty Liver Disease?一决高下：哪种纤维化筛查工具对非酒精性脂肪性肝病最可靠？
Dig Dis Sci. 2023 Jun;68(6):2217-2220. doi: 10.1007/s10620-023-07899-0. Epub 2023 Mar 22.
4
Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?“高危”非酒精性脂肪性肝病患者的非侵入性诊断：仅纤维化起作用吗？
Gut. 2020 Jul;69(7):1164-1165. doi: 10.1136/gutjnl-2020-320785. Epub 2020 Mar 27.
5
Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.用于非酒精性脂肪性肝炎和肝纤维化诊断的单核细胞表型液体活检：初来乍到的新方法
Gut. 2023 Dec 7;73(1):10-11. doi: 10.1136/gutjnl-2022-328189.
6
Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.采用非侵入性方法准确诊断非酒精性脂肪性肝病相关肝纤维化：前进之评论
J Hepatol. 2020 Aug;73(2):465-466. doi: 10.1016/j.jhep.2020.03.020. Epub 2020 May 13.
7
The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病纤维化无创评估工具的相关性。
Curr Pharm Des. 2020;26(32):3928-3938. doi: 10.2174/1381612826666200521133307.
8
Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?慢性肝病的肝活检：是否存在有利的获益风险平衡？
Ann Hepatol. 2017 Jul-Aug;16(4):487-489. doi: 10.5604/01.3001.0010.0272.
9
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中肝纤维化的非侵入性生物标志物
Clin Mol Hepatol. 2023 Apr;29(2):398-400. doi: 10.3350/cmh.2023.0045. Epub 2023 Feb 13.
10
Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.非酒精性脂肪性肝病——组织学评分系统：一项大型队列单中心评估研究。
APMIS. 2017 Nov;125(11):962-973. doi: 10.1111/apm.12742.
引用本文的文献
1
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.小檗碱在非酒精性脂肪性肝病纤维化前期的作用——临床与临床前概述及文献系统综述
Int J Mol Sci. 2024 Apr 10;25(8):4201. doi: 10.3390/ijms25084201.
2
Evolutive Models, Algorithms and Predictive Parameters for the Progression of Hepatic Steatosis.肝脂肪变性进展的演变模型、算法及预测参数
Metabolites. 2024 Apr 3;14(4):198. doi: 10.3390/metabo14040198.
3
LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis.LEARN算法：预测非酒精性脂肪性肝炎的一种新方法。
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):507-522. doi: 10.21037/hbsn-21-523. Epub 2023 Mar 30.
4
Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease.次级胆汁酸可改善非酒精性脂肪性肝病患者非侵入性识别轻度肝纤维化的风险预测。
Aliment Pharmacol Ther. 2023 Apr;57(8):872-885. doi: 10.1111/apt.17362. Epub 2023 Jan 20.
5
A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.基于T2加权成像的新型放射组学特征可准确预测经活检证实的非酒精性脂肪性肝病患者的肝脏炎症：一项推导和独立验证研究。
Hepatobiliary Surg Nutr. 2022 Apr;11(2):212-226. doi: 10.21037/hbsn-21-23.
6
Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.经活检证实的非酒精性脂肪性肝病患者肝纤维化诊断的潜在血液DNA甲基化生物标志物基因
Front Med (Lausanne). 2022 Mar 31;9:864570. doi: 10.3389/fmed.2022.864570. eCollection 2022.
7
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.非酒精性脂肪性肝炎与肝细胞癌风险。
Chin Med J (Engl). 2021 Dec 1;134(24):2911-2921. doi: 10.1097/CM9.0000000000001888.
8
Consensus scoring systems for nonalcoholic fatty liver disease: an unmet clinical need.非酒精性脂肪性肝病的共识评分系统：一项未满足的临床需求。
Hepatobiliary Surg Nutr. 2021 Jun;10(3):388-390. doi: 10.21037/hbsn-21-80.
本文引用的文献
1
Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.开发和验证一种新型无创检测方法，用于诊断经活检证实的非酒精性脂肪性肝病患者的纤维化非酒精性脂肪性肝炎。
J Gastroenterol Hepatol. 2020 Oct;35(10):1804-1812. doi: 10.1111/jgh.15055. Epub 2020 Apr 28.
2
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎纤维化发展的机制。
Gastroenterology. 2020 May;158(7):1913-1928. doi: 10.1053/j.gastro.2019.11.311. Epub 2020 Feb 8.
3
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. FibroScan-AST (FAST) 评分用于无创识别有显著活动度和纤维化的非酒精性脂肪性肝炎患者：一项前瞻性推导和全球验证研究。
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3.
4
Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.载脂蛋白 PLA3 基因多态性对各种非侵入性标记物诊断和分期非酒精性脂肪性肝病的诊断性能的影响。
J Gastroenterol Hepatol. 2020 Jun;35(6):1057-1064. doi: 10.1111/jgh.14894. Epub 2019 Dec 9.
5
Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.Hepamet纤维化评分系统的开发与验证——一种用于识别非酒精性脂肪性肝病伴晚期纤维化患者的简单无创检测方法
Clin Gastroenterol Hepatol. 2020 Jan;18(1):216-225.e5. doi: 10.1016/j.cgh.2019.05.051. Epub 2019 Jun 11.
6
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝脏疾病的无创评估。
Gastroenterology. 2019 Apr;156(5):1264-1281.e4. doi: 10.1053/j.gastro.2018.12.036. Epub 2019 Jan 18.
7
ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.ADAPT：一种纳入 PRO-C3 的算法可准确识别非酒精性脂肪性肝病伴进展性肝纤维化患者。
Hepatology. 2019 Mar;69(3):1075-1086. doi: 10.1002/hep.30163.
8
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的无创性生物标志物：当前进展与未来前景。
Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9.
9
Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH.临床实践中的治疗试验和治疗指征筛查：MACK-3，一种用于诊断纤维化 NASH 的新型血液检测方法。
Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25.
10
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.非酒精性脂肪性肝病的无创评估：临床预测规则和基于血液的生物标志物。
J Hepatol. 2018 Feb;68(2):305-315. doi: 10.1016/j.jhep.2017.11.013. Epub 2017 Dec 2.
Zotero 插件